Department of Nuclear Medicine and Institute of Wonkwang Medical Science, Wonkwang University School of Medicine, 344-2 Shinyong-Dong, Iksan, Jeollabuk-do 570-711, Republic of Korea.
Endocrine. 2012 Oct;42(2):399-403. doi: 10.1007/s12020-012-9636-9. Epub 2012 Feb 18.
In evaluating cervical lymph node (LN) metastasis from papillary thyroid cancer (PTC), ultrasonography (US)-guided fine-needle aspiration biopsy (FNAB) is very important tool. There were limited number of studies about the diagnostic value of thyroglubion measurement in FNAB (FNAB-Tg) in non-thyroidectomized patients. Therefore, in this study, the authors evaluated the role of FNAB-Tg in diagnosing cervical LN metastases in patients with PTC before thyroidectomy. A total 91 suspicious LNs of 68 patients were undergone US-guided FNAB-Tg and cytology. Any FNAB-Tg concentration above 50 ng/ml considered as positive, irrespective of thyroid gland presence. Based on the final pathology, 49 LNs were positive, and the remaining 42 LNs were negative for metastasis. The sensitivity, specificity, and accuracy of FNAB-Tg in thyroidectomized patients were 80.0, 100.0, and 88.9%, respectively. The diagnostic performance of FNAB-Tg was not compromised by the presence of thyroid gland (sensitivity, specificity and accuracy = 95.0, 90.9 and 93.2%, respectively). FNAB-Tg is useful and simple method for the diagnosis of metastatic cervical LNs from PTC. The diagnostic performance of FNAB-Tg was not compromised by the presence of thyroid gland. Therefore, FNAB-Tg could be performed actively for the LN staging of PTC.
在评估甲状腺乳头状癌(PTC)的颈部淋巴结(LN)转移时,超声引导下细针穿刺活检(FNAB)是非常重要的工具。关于非甲状腺切除患者中 FNAB 中甲状腺球蛋白测量(FNAB-Tg)的诊断价值的研究数量有限。因此,在这项研究中,作者评估了 FNAB-Tg 在甲状腺切除术前诊断 PTC 患者颈部 LN 转移中的作用。共对 68 例 91 个可疑淋巴结进行了超声引导下 FNAB-Tg 和细胞学检查。无论甲状腺是否存在,任何 FNAB-Tg 浓度高于 50ng/ml 均被认为是阳性。根据最终病理,49 个淋巴结为阳性,42 个淋巴结为阴性。FNAB-Tg 在甲状腺切除患者中的敏感性、特异性和准确性分别为 80.0%、100.0%和 88.9%。FNAB-Tg 的诊断性能不受甲状腺的存在影响(敏感性、特异性和准确性分别为 95.0%、90.9%和 93.2%)。FNAB-Tg 是一种有用且简单的方法,可用于诊断 PTC 的转移性颈部 LN。FNAB-Tg 的诊断性能不受甲状腺的存在影响。因此,FNAB-Tg 可积极用于 PTC 的 LN 分期。